Skip to main content
Decorative image of the AMR Learning Lounge

Early empiric antibiotic use in COVID-19 patients: results from the international VIRUS registry

SUMMARY

International Journal of Infectious Diseases | December 19, 2023 

With the increased demand for hospitalization that COVID-19 generated around the world, came the escalation of inappropriate antibiotic use. 

Results from the Society of Critical Care Medicine Discovery VIRUS international COVID-19 Registry aim to determine the rate and factors associated with early empiric antibiotic (EEAB) treatment to help set goals for antimicrobial stewardship efforts, in the post-pandemic era.

Featured Experts

Uluhan Sili MD, PhD, Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Türkiye  

Aysun Tekin MD, Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA 

Huseyin Bilgin MD, MPH, Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Türkiye et al 

GET STARTED

Read more about this important research ➡

Learn More!

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll
U.S. bioMérieux Solutions

GLOBAL Solutions

BIOFIRE® SPOTFIRE® Respiratory /Sore Throat Panels

The BIOFIRE Respiratory/Sore Throat (R/ST) Panels enable testing for both respiratory or sore throat pathogens on the same panel, providing a flexible respiratory solution to meet the unique needs of point-of-care settings.

Learn More
U.S. bioMérieux Solutions

US Solutions

Diagnose respiratory pathogens quickly and accurately with the BioFire® Respiratory 2.1 (RP2.1) Panel

SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. The FDA De Novo authorized BioFire RP2.1 Panel is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.

Learn More

PUBLISHED ON

May 6, 2024

SHARE THIS ARTICLE: